1542 results about "Heart failure" patented technology

Interatrial shunts are described herein that are designed to benefit both the left side of the heart and the right side of the heart. The interatrial shunt is anchored in the atrial septum to permit blood to flow between atrial heart chambers across the atrial septum. In accordance with some aspects, the lumen of the shunt has an effective orifice area selected to permit blood flow across the atrial septum to unload the patient's left ventricle with beneficial effects on the patient's right ventricle. The shunts are structured to be suitably anchored at the atrial septum for long-term implantation. Further, the shunts preferably have insignificant late lumen loss. The interatrial shunts are expected to treat pathologies such as heart failure and pulmonary hypertension.

The invention provides an AI-based heart failure risk assessment method and system, and relates to the technical field of artificial intelligence, and the method comprises the steps: recognizing a mutation point of a physiological index time sequence through a recursive segmentation algorithm, extracting a mutation feature matrix, carrying out the time sequence mapping, recognizing a periodic mutation and gradual change mode, and converting into a risk score to generate a risk accumulation curve. Calculating index conduction time delay, drawing a risk conduction path diagram, marking an intervention time window, and finally determining a heart failure risk level and generating an evaluation report. According to the invention, early accurate recognition of the heart failure risk can be realized, and the best opportunity is provided for clinical intervention.

Various systems, devices, and methods are disclosed herein for treating acute myocardial infarction (AMI) patients using a heart pump controlled in a manner that maximizes mechanical unloading of the left ventricle in the presence of cardiovascular instability and minimizes myocardial oxygen consumption (MVO2) and consequentially infarct size to prevent the development of subsequent heart failure. In a closed feedback system, the system can include a sensor configured to generate an output used to measure or calculate a left ventricular systolic pressure (LSVP) within the left ventricle of a heart and a controller coupled to a heart pump. The controller can be configured to measure or calculate the LVSP based on the output of the sensor and to control an operation of the heart pump to maximize mechanical unloading of the left ventricle based on the measured or calculated LVSP.

To provide a device assembly and a method for treating heart failure by normalizing an elevated blood pressure in the left atrium of the heart of a mammal.SOLUTION: Disclosed herein is a transcatheter interatrial septum excision device assembly configured to create a sized interatrial aperture between right and left atria of a heart for relief of an elevated left atrial pressure. The device assembly comprises a delivery catheter, a tissue stabilizer attached to a first catheter having a central lumen and a penetrating tip that permits passage of a guidewire, and a cutter attached to a second catheter having a central lumen that permits passage of the first catheter. Alternative configurations comprise a (third) catheter having a central lumen that permits passage of the components to and from the right atrium, a tissue retention mechanism, and an optional coaxial alignment mechanism.SELECTED DRAWING: Figure 1

The invention relates to the technical field of heart blood pumps, in particular to a passive ventricular auxiliary circulation device. Comprising a motor body shell, a stator and a rotor are arranged in the motor body shell, and one of the stator and the rotor comprises a coil; the axial flow channel shell is sleeved; the upper end of the axial flow channel shell is configured to face the aortic valve to the lower part of the ventricle, and a power supply configured to be operably coupled to the coil; and the controller is configured to be operated and coupled to the power supply to select and control the power supply to change the rotor to a certain rotating speed in a manual selection mode, then the rotor keeps working in a certain rotating speed mode, and corresponding auxiliary pressure output by the fluid outlet interface is configured at a different rotating speed. The device is controlled to be in a rotating speed state, and when systolic pressure smaller than normal systolic pressure is provided for cardiac pulsation of a heart failure patient, the normal systolic pressure is provided when the systolic pressure and auxiliary pressure are overlapped together, so that the heart failure patient maintains the normal systolic pressure.

The invention relates to the technical field of medical health information, in particular to a heart failure risk prediction method and system based on multi-source heterogeneous data fusion, and the prediction system comprises a data collection module, a data management module, a multi-modal feature extraction module and a dynamic risk prediction model module. An intervention strategy recommendation module; and a visualization and iterative optimization module. The prediction method is applied to the prediction system, patient health data is collected and obtained, a multi-source heterogeneous health database is constructed, physiological time sequence features, traditional Chinese medicine dialectical features and western medicine clinical features are extracted respectively to be subjected to structured coding processing, a multi-modal feature set is formed, the multi-modal feature set is divided into a training set, a verification set and a test set, and the training set, the verification set and the test set are combined. A Bayesian attention mechanism is introduced, dynamic prediction of the heart failure risk is achieved through the constructed depth time sequence model, an intervention scheme can be adjusted and formulated in the whole course of heart failure management, excessive medical treatment is reduced, meanwhile, disease progress is effectively restrained or delayed, and the life quality of a patient is improved.

The invention discloses a heart failure treatment aid decision generation system based on multi-modal data fusion, and the system comprises a data collection module which is used for collecting the multi-modal data of a patient, and the multi-modal data comprises structured data, unstructured data and medical image data; the data processing module is used for carrying out standardization, quantization and vectorization processing on the multi-modal data; the knowledge graph construction module is used for constructing a knowledge graph of heart failure treatment, and the knowledge graph comprises a disease entity, a pathological feature, a treatment scheme and an association relationship thereof; the reasoning module is used for generating a personalized treatment decision based on the knowledge graph and the patient data; and the treatment scheme generation module is used for dynamically adjusting and outputting a personalized treatment scheme in combination with the real-time state data of the patient. The problems that multi-modal data are difficult to fuse and real-time disease change is difficult to dynamically adjust in heart failure diagnosis and treatment are solved, accurate diagnosis and personalized treatment are realized through knowledge graph reasoning and a dynamic correction mechanism, and the diagnosis and treatment efficiency and accuracy are remarkably improved.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

To provide formulations for treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease.SOLUTION: The invention provides a chemical formulation for use in a method of treating a disease, the method comprising: inserting a delivery catheter into a vascular lumen adjacent to nerves, where the vascular lumen includes a pulmonary artery; infusing the chemical formulation into the vascular lumen through the delivery catheter, where the amount of the chemical formulation is an amount effective to injure or damage the nerves and provide benefits in alleviating the symptoms of the disease; and withdrawing the delivery catheter from the blood vessel. The chemical formulation is at least one of 10-100 wt.% of ethanol, and 1-100 wt.% of acetic acid. The disease includes pulmonary arterial hypertension.SELECTED DRAWING: None

The invention discloses application of an AXL inhibitor in preparation of a medicine for treating heart failure, and relates to the field of pharmacy. The invention provides application of an AXL inhibitor in a medicine for treating heart failure. The AXL inhibitor can remarkably inhibit abnormal activation of fibroblasts and can remarkably improve the heart function of a mouse with heart failure.

The invention discloses a heart failure patient remote monitoring and early warning system based on the Internet of Things, and the system comprises a data collection and preprocessing module which is used for collecting and preprocessing multi-source physiological and behavior data, and generating an input sample set; the feature evaluation module is used for constructing an extreme gradient boosting tree algorithm model and obtaining feature importance scores; the feature screening module is used for executing a recursive feature elimination process and outputting an optimal feature subset; the risk judgment module is used for inputting the optimal feature subset into an extreme gradient boosting tree algorithm model to generate a heart failure risk score; the early warning triggering module is used for triggering early warning and sending early warning information to the patient and the platform; the feedback recording module is used for generating feedback information; and the dynamic optimization module is used for updating the input sample set based on the feedback information, retraining the extreme gradient boosting tree algorithm model and screening the features. According to the method, the extreme gradient boosting tree and recursive feature elimination are fused, and accurate evaluation and dynamic early warning of the multi-source data of the heart failure patient are realized.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention relates to the technical field of medical instruments, and discloses an intelligent device for monitoring the cardio-pulmonary function of a heart failure patient, the intelligent device comprises a multi-mode sensor module, an AI analysis module, a biological feedback module and a wearable carrier, the multi-mode sensor module is used for collecting heart rate, respiratory rate, oxyhemoglobin saturation and body movement data in real time, and the AI analysis module is used for analyzing the heart rate, the respiratory rate, the oxyhemoglobin saturation and the body movement data; monitoring modes can be dynamically switched in rest, motion and sleep scenes; the AI analysis module is used for detecting abnormity based on real-time data and predicting a heart failure deterioration risk in combination with historical data; and the biological feedback module is used for providing personalized intervention in a vibration or audio mode according to the analysis result. The heart rate, the respiration rate, the blood oxygen saturation and the body movement data are collected at the same time through the multi-mode sensor module, sleep apnea or periodic respiration is recognized in combination with the AI analysis module, the defect of separation of cardiopulmonary function monitoring and sleep mode analysis in the prior art is overcome, and therefore early intervention and treatment adjustment are supported.

The invention relates to a heart failure home patient-oriented multivariable trend anomaly detection method, which comprises the following steps of: constructing an initial contour of a multivariable health trend for a patient, and introducing a trend inertia vector: updating trend inertia to form an individual trend trajectory relationship; detecting an inertia breaking point in the trend trajectory diagram; analyzing whether the variables within 12-36 hours before and after the focusing breaking point analysis generate collaborative disturbance or not; performing reprocessing through a disturbance amplification operator to form a potential early warning factor; constructing a multivariable intervention graph by using the disturbance cooperation matrix; monitoring the offset direction and strength of the causal propagation chain on each path; if the plurality of paths are subjected to direction deviation in the same period at the same time, judging that the deviation is pathological trend deviation; converting the causal offset path into a single trend risk factor, spreading a plurality of weak signals in a variable graph, evaluating systematic influence, forming a fuzzy risk scoring curved surface relationship, and outputting an individual trend risk level; the sensitivity and continuity of trend identification are improved, individual differences are adapted, and the false alarm rate is reduced.

The invention provides an anti-S100A8 / A9 antibody and application of the anti-S100A8 / A9 antibody. The antibody or the antigen binding fragment and the mutant thereof provided by the invention can block the biological function of S100A8 / A9. The antibody or the antigen binding fragment provided by the invention is expected to be developed into a clinical drug, so that the cardiac infarction area of an AMI patient is reduced, the occurrence of heart failure is reduced, the AMI patient is benefited for the whole life, and the antibody or the antigen binding fragment has important clinical significance and development value.

Interatrial shunts having incorporated physiologic sensors are provided for monitoring and treating cardiovascular syndromes, including heart failure and pulmonary hypertension, in which the one or more sensors are affixed to the shunt to measure a physiologic parameter within the interatrial shunt. The one or more sensors may be directly affixed to or within a lumenal surface of the shunt or may be disposed on a support structure in a spaced relation to the shunt lumen, the one or more sensors disposed at locations subject to little or no pannus formation or cardiac wall motion artifact.

Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.

A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.

A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.

The invention discloses a heart failure combined left beam branch conduction block classification method based on feature fusion, and the method comprises the steps: extracting radiomics features and deep learning features through a heart magnetic resonance image, carrying out the feature fusion and selection, constructing a classification model through a machine learning algorithm, and carrying out the classification of the heart failure combined left beam branch conduction block. According to the method, the advantages of deep learning in the aspect of image processing and the high efficiency of machine learning in a classification task are combined, and complex information of a heart image can be reflected more comprehensively and accurately by combining radiomics features and deep learning features; an automatic and intelligent feature extraction and classification method is utilized, a large amount of medical image data can be rapidly processed and analyzed, accurate classification of the heart failure combined left bundle branch conduction block is achieved, the method has higher classification accuracy and higher robustness, and in the field of medical image classification, the method has the advantages that the classification accuracy is improved, and the classification efficiency is improved. And the efficiency and the quality of medical services can be improved.

An aorta intervention catheter device for heart failure comprises a catheter and a bag body arranged at one end of the catheter, an elastic diaphragm is arranged in the bag body, an inner cavity of the bag body is divided into a blood chamber and an air chamber by the elastic diaphragm, the blood chamber is communicated with the catheter, an exhaust assembly is arranged on the bag body, and the air chamber is connected with an air source connector arranged on the bag body; the other end of the catheter is a proximal end, first guide films which are staggered at intervals and inclined towards one side of the proximal end and second guide films which are inclined towards a distal end are arranged on the inner wall of the catheter, and first guide holes and second guide holes which correspond to the first guide films and the second guide films and are communicated with an inner cavity of the catheter are respectively formed in the outer wall of the catheter; the proximal side of the second guide film is provided with at least one set of third guide films which are fixed to the inner wall of the catheter, incline towards the distal end and are tightly attached to each other to be closed. The aorta is directly intervened to enter the heart, and coronary artery blood perfusion is increased in the diastolic period; the left ventricular post-load is reduced in the systolic period, and the heart failure can be more directly treated.

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and / or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

The invention relates to the technical field of intelligent medical treatment and traditional Chinese medicine diagnosis and treatment, in particular to a traditional Chinese medicine heart failure intelligent diagnosis and treatment system and method based on machine vision, and the diagnosis and treatment method comprises the steps: collecting a tongue image and a face image of a patient and an infrared thermogram of a corresponding part, and carrying out the preprocessing of the collected tongue image, face image and infrared thermogram; features in the tongue image, the face image and the infrared thermal image are quantified into tongue image feature vectors, face feature vectors and temperature feature vectors by using different algorithms, a multi-modal fusion deep learning model is established, and the feature vectors are input into the multi-modal fusion deep learning model for training; and inputting the collected tongue image, the face image and the infrared thermal image into a multi-modal fusion deep learning model, outputting a diagnosis result, and carrying out visual display. The diagnosis and treatment system is applied to the diagnosis and treatment method, the system can objectively quantify traditional Chinese medicine diagnosis information, the sensitivity of early recognition is remarkably improved, and the accuracy and efficiency of diagnosis are improved.

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Disclosed are systems and methods for assessment, management, and treatment of congestion in heart failure. The systems and methods may include or relate to wireless implants, reader modules, and uses thereof, which are configured to measure hemodynamic parameters of a patient in different patient states and positions. For example, the reader module may be hands free. For example, the reader module may be used at home by a patient. The reader module may be able to take readings and measurements when the patient is in a multitude of positions, including but not limited to, the supine and the prone positions. The reader module may be able to communicate and receive data from an implanted device when in a certain proximity of the implanted device and may be able to store, analyze, and / or transmit data to a different wireless device over a network, for example. In an embodiment, the reader module may be portable and wearable, e.g., through use of a garment or strap.